The first was to evaluate an anti-CD22 MAb conjugate, 227Th-epratuzumab (BAY1862864), to establish the dose in patients with CD22 positive non-Hodgkin’s lymphoma (NHL), and in the second trial, a 227Th-labeled MAb conjugate (BAY2287411) was used to evaluate the safety and maximum dose in patients with epithelioid malignant mesothelioma and ovarian cancer [5]. This evidence concerns the gene CD22 and ovarian carcinoma.